CEL-SCI Home Page
preload preload

February 2016

CEL-SCI CEO on Fox

April 2017

CEL-SCI Shareholder Letter

Press Releases

Corporate Presentations

Press Releases

June 12, 2017
NEW STORY CEL-SCI Announces Reverse Stock Split

June 8, 2017
NEW STORY CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal

June 7, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016

June 5, 2017
NEW STORY CEL-SCI Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial

May 24, 2017
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders

May 16, 2017
NEW STORY CEL-SCI Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting

May 12, 2017
NEW STORY CEL-SCI Announces Change to the Date of Its Annual Meeting

May 10, 2017
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results

May 1, 2017
NEW STORY CEL-SCI Announces $1.51 Million Registered Direct Offering

April 28, 2017
NEW STORY CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office

April 24, 2017
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders

April 12, 2017
NEW STORY CEL-SCI Scientist Presents at the World Vaccine Congress

March 9, 2017
NEW STORY CEL-SCI Announces $1.5 Million Registered Direct Offering

March 6, 2017
NEW STORY CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine

February 27, 2017
NEW STORY CEL-SCI Announces That the NYSE MKT Approves Plan

February 21, 2017
NEW STORY CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference

February 17, 2017
NEW STORY CEL-SCI Announces $1.0 Million Registered Direct Offering

February 9, 2017
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

December 20, 2016
NEW STORY CEL-SCI Announces Closing of Public Offering and Receives Audit Opinion with Going Concern Explanation

December 14, 2016
NEW STORY CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments

December 9, 2016
NEW STORY CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan

December 2, 2016
NEW STORY CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants

December 1, 2016
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants

November 21, 2016
NEW STORY CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial

November 14, 2016
NEW STORY CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

October 21, 2016
NEW STORY CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial

September 26, 2016
NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study

September 6, 2016
NEW STORY CEL-SCI Announces Resignation of Its Founder for Health Reasons

September 2, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial

 

ADDITIONAL RELEASES
View All Corporate Press Releases


Phase III Clinical Trial Monthly Enrollment Chart

Number of Patients Enrolled per month since the transfer to the new CROs.

Phase III Enrollment Chart


 

THE CEL-SCI STORY